Findings

What do systematic reviews say?

1,060 questions · 1,105 findings · 84 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 434 · 39.3%GRADE not reported 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%

Meglitinides vs sulphonylureas

HbA1c (%)

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 235 participants
Very low

SGLT‐2 inhibitors vs sulphonylureas

Hypoglycaemic episodes a) Non‐serious hypoglycaemia

It is very uncertain whether SGLT‐2 inhibitors changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with sulphonylureas (very low certainty).

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
RR 0.28 [0.1, 0.79]
1 study · 110 participants
Very low

SGLT‐2 inhibitors vs sulphonylureas

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SGLT‐2 inhibitors vs sulphonylureas

Adverse events other than hypoglycaemia

It is very uncertain whether SGLT‐2 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
RR 1 [0.6, 1.67]
1 study · 110 participants
Very low

SGLT‐2 inhibitors vs sulphonylureas

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SGLT‐2 inhibitors vs sulphonylureas

Treatment satisfaction

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SGLT‐2 inhibitors vs sulphonylureas

HbA1c (%)

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 103 participants
Low

DPP‐4 inhibitors vs sulphonylureas

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GLP‐1 analogues inhibitors vs sulphonylureas

Hypoglycaemic episodes a) Non‐serious hypoglycaemia

It is very uncertain whether GLP‐1 analogues inhibitors changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with sulphonylureas (very low certainty).

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
RR 0.45 [0.28, 0.74]
3 studies · 596 participants
Very low

GLP‐1 analogues inhibitors vs sulphonylureas

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GLP‐1 analogues inhibitors vs sulphonylureas

Adverse events other than hypoglycaemia

It is very uncertain whether GLP‐1 analogues inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
RR 1.5 [0.86, 2.61]
3 studies · 499 participants
Very low

GLP‐1 analogues inhibitors vs sulphonylureas

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

GLP‐1 analogues inhibitors vs sulphonylureas

Treatment satisfaction

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Very low

GLP‐1 analogues inhibitors vs sulphonylureas

HbA1c (%)

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 246 participants
Low

Insulin analogues vs biphasic insulin

Hypoglycaemic episodes a) Non‐serious hypoglycaemia

It is very uncertain whether insulin analogues changes hypoglycaemic episodes a) Non‐serious hypoglycaemia compared with biphasic insulin (very low certainty).

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
RR 0.43 [0.13, 1.4]
2 studies · 500 participants
Very low

Insulin analogues vs biphasic insulin

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Insulin analogues vs biphasic insulin

Adverse events other than hypoglycaemia

It is very uncertain whether insulin analogues changes any adverse events other than hypoglycaemia compared with biphasic insulin (very low certainty).

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
RR 0.83 [0.44, 1.56]
2 studies · 500 participants
Very low

Insulin analogues vs biphasic insulin

All‐cause mortality

It is very uncertain whether insulin analogues changes all‐cause mortality compared with biphasic insulin (very low certainty).

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
RR 3.02 [0.12, 73.53]
1 study · 263 participants
Very low

DPP‐4 inhibitors vs sulphonylureas

Adverse events other than hypoglycaemia

It is very uncertain whether DPP‐4 inhibitors changes adverse events other than hypoglycaemia compared with sulphonylureas (very low certainty).

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
RR 0.9 [0.52, 1.54]
3 studies · 2426 participants
Very low

Insulin analogues vs biphasic insulin

Treatment satisfaction

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found